Switch theme
Sign up to access all valuation multiples
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
2017
268
LTM Revenue $751M
LTM EBITDA $253M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harmony Biosciences Hldgs has a last 12-month revenue of $751M and a last 12-month EBITDA of $253M.
In the most recent fiscal year, Harmony Biosciences Hldgs achieved revenue of $715M and an EBITDA of $233M.
Harmony Biosciences Hldgs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harmony Biosciences Hldgs valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $582M | $715M | XXX | XXX | XXX |
| Gross Profit | $354M | $461M | XXX | XXX | XXX |
| Gross Margin | 61% | 64% | XXX | XXX | XXX |
| EBITDA | $222M | $233M | XXX | XXX | XXX |
| EBITDA Margin | 38% | 33% | XXX | XXX | XXX |
| Net Profit | $181M | $129M | XXX | XXX | XXX |
| Net Margin | 31% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Harmony Biosciences Hldgs's stock price is $30.
Harmony Biosciences Hldgs has current market cap of $1.7B, and EV of $1.4B.
See Harmony Biosciences Hldgs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.7B | XXX | XXX | XXX | XXX | $2.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Harmony Biosciences Hldgs has market cap of $1.7B and EV of $1.4B.
Harmony Biosciences Hldgs's trades at 1.9x LTM EV/Revenue multiple, and 5.6x LTM EBITDA.
Analysts estimate Harmony Biosciences Hldgs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Harmony Biosciences Hldgs and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | XXX | XXX |
| P/E | 11.6x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | 6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHarmony Biosciences Hldgs's NTM/LTM revenue growth is 18%
Harmony Biosciences Hldgs's revenue per employee for the last fiscal year averaged $2.7M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Harmony Biosciences Hldgs's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Harmony Biosciences Hldgs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Harmony Biosciences Hldgs and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 51% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harmony Biosciences Hldgs acquired XXX companies to date.
Last acquisition by Harmony Biosciences Hldgs was XXXXXXXX, XXXXX XXXXX XXXXXX . Harmony Biosciences Hldgs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Harmony Biosciences Hldgs founded? | Harmony Biosciences Hldgs was founded in 2017. |
| Where is Harmony Biosciences Hldgs headquartered? | Harmony Biosciences Hldgs is headquartered in United States of America. |
| How many employees does Harmony Biosciences Hldgs have? | As of today, Harmony Biosciences Hldgs has 268 employees. |
| Who is the CEO of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's CEO is Dr. Jeffrey M. Dayno, M.D.. |
| Is Harmony Biosciences Hldgs publicy listed? | Yes, Harmony Biosciences Hldgs is a public company listed on NAS. |
| What is the stock symbol of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs trades under HRMY ticker. |
| When did Harmony Biosciences Hldgs go public? | Harmony Biosciences Hldgs went public in 2020. |
| Who are competitors of Harmony Biosciences Hldgs? | Similar companies to Harmony Biosciences Hldgs include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's current market cap is $1.7B |
| What is the current revenue of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's last 12-month revenue is $751M. |
| What is the current EBITDA of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs's last 12-month EBITDA is $253M. |
| What is the current EV/Revenue multiple of Harmony Biosciences Hldgs? | Current revenue multiple of Harmony Biosciences Hldgs is 1.9x. |
| What is the current EV/EBITDA multiple of Harmony Biosciences Hldgs? | Current EBITDA multiple of Harmony Biosciences Hldgs is 5.6x. |
| What is the current revenue growth of Harmony Biosciences Hldgs? | Harmony Biosciences Hldgs revenue growth between 2023 and 2024 was 23%. |
| Is Harmony Biosciences Hldgs profitable? | Yes, Harmony Biosciences Hldgs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
